Bronchiolitis News and Research

RSS

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Meningococcal disease in infants: A potentially difficult and serious diagnosis

An article published in the May 2010 edition of Postgraduate Medicine documents a case study where a previously healthy, 15-week-old male infant was misdiagnosed and died of meningococcal disease. Initially the patient showed signs of the common cold and was treated as such, but symptoms worsened and he was admitted to the hospital emergency department.

16 Jun 2010

University of Montreal scientists discover free radical mechanism to viral invasion

Canadian researchers have discovered a new way the body combats respiratory viral infections. In the prestigious journal PLoS Pathogens, scientists from the University of Montreal and the University of Montreal Hospital Research Center explain how the NOX2 molecule, an enzyme that generates a burst of highly reactive oxygen derivatives (or free radicals), activates defense genes and molecules when viruses invade lung cells.

16 Jun 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights.

6 May 2010

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has published results from its Phase II GEMINI study in the Proceedings of the National Academy of Sciences (PNAS). These data, previously presented at the International Symposium on Respiratory Viral Infections in Singapore in 2008, showed human proof of concept with an RNAi therapeutic in a randomized, double blind, placebo-controlled study.

27 Apr 2010

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial in adult lung transplant patients with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. RSV infection in lung transplant patients represents an important unmet medical need; the condition is associated with significant morbidity, including the development of acute lung transplant rejection in 10% to 20% of infected patients.

22 Feb 2010

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.

11 Feb 2010

Brazilian researchers perform autopsy study to examine the causes H1N1 death

Brazilian researchers have performed the first-ever autopsy study to examine the precise causes of death in victims of the H1N1 swine flu.

23 Dec 2009

Lung disease linked to the use of contaminated well water in a CPAP machine

Many people rely on continuous positive airway pressure (CPAP) machines as a safe and effective treatment for sleep apnea. But a new case report describes a rare complication—a lingering inflammatory disease of the lungs, apparently related to the use of contaminated well water in a CPAP machine. The report appears in the December Southern Medical Journal, official journal of the Southern Medical Association.

3 Dec 2009

Respiratory syncytial virus, the most common cause of pneumonia in children

RSV is a respiratory virus that infects the lungs and breathing passages. While most healthy people recover from RSV infection, it can be severe in infants. According to the United States Centers for Disease Control and Prevention (CDC), RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the nation.

3 Dec 2009

RSV found to cause more emergency department visits and hospitalizations than seasonal flu

Influenza, particularly H1N1, has understandably captured the attention of public health officials, the media and the public. However, an analysis from Children's Hospital Boston, based on patients seen in its emergency department (ED) during several recent flu seasons, shows that another virus - respiratory syncytial virus (RSV) - takes a substantially greater disease toll among young children than does seasonal flu.

23 Nov 2009

Exposure to higher levels of air pollution increases infants' risk for bronchiolitis

Infants who are exposed to higher levels of air pollution are at increased risk for bronchiolitis, according to a new study.

6 Nov 2009

Four abstracts on RSV and influenza prevention in pediatric health to be presented

MedImmune announced today it will present four abstracts at the 47th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 29 through November 1, 2009. These abstracts advance the body of data surrounding respiratory syncytial virus (RSV) and influenza prevention, highlighting MedImmune's leadership in pediatric health.

31 Oct 2009

Children born four months before height of cold and flu season have a greater risk of developing childhood asthma

It is said that timing is everything, and that certainly appears to be true for autumn infants.

21 Nov 2008

New Imperial College centre to tackle respiratory infections

Think that colds and flu are easy to catch, hard to avoid and impossible to treat? That nobody ever dies of a cold? That's all wrong, say the medics and scientists at a new research centre which launches today (Monday 2 June).

1 Jun 2008

Iraq war and risk of developing bronchiolitis

A large group of soldiers returning from Iraq have been diagnosed with bronchiolitis, a disease affecting the small airways of the lung, according to Vanderbilt University Medical Center physicians who will present their findings at the American Thoracic Society's 2008 International Conference in Toronto on Wednesday, May 21.

21 May 2008